Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPCAM CAR-T (Zhejiang University)
- Development stage
- Unknown
- Lead developer
- Immunofoco
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EPCAM CAR-T (specifically the candidate IMC-001) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the Epithelial Cell Adhesion Molecule (EpCAM). EpCAM is a transmembrane glycoprotein that is highly expressed in various epithelial carcinomas, including gastric, colorectal, liver, and pancreatic cancers, while showing limited expression in normal tissues, making it a suitable target for immunotherapy. The treatment involves isolating a patient's T cells, genetically engineering them to express a CAR specific for EpCAM, and re-infusing them into the patient to induce a targeted anti-tumor immune response. Developed by Zhejiang University, this therapy is being evaluated in Phase I clinical trials for the treatment of advanced digestive system malignancies.
- Other names
- EpCAM CAR-TEpCAM-targeting CAR-T cellsautologous EpCAM-targeting CAR-T cellsEpCAM-specific CAR-T cells
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on EPCAM CAR-T (Zhejiang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPCAM CAR-T (Zhejiang University).